CN116870065A - 一种复方优基诺抗癌中药靶向制剂及其制作工艺 - Google Patents
一种复方优基诺抗癌中药靶向制剂及其制作工艺 Download PDFInfo
- Publication number
- CN116870065A CN116870065A CN202211530592.9A CN202211530592A CN116870065A CN 116870065 A CN116870065 A CN 116870065A CN 202211530592 A CN202211530592 A CN 202211530592A CN 116870065 A CN116870065 A CN 116870065A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- keno
- youkeno
- anticancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 62
- 150000001875 compounds Chemical class 0.000 title claims abstract description 43
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 37
- 230000008685 targeting Effects 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title description 8
- 230000008569 process Effects 0.000 title description 3
- 239000000843 powder Substances 0.000 claims abstract description 32
- 241000402754 Erythranthe moschata Species 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- 238000011282 treatment Methods 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000008517 radix Trichosanthis Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000007667 floating Methods 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 22
- 201000011510 cancer Diseases 0.000 abstract description 14
- 210000004881 tumor cell Anatomy 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 4
- 230000006907 apoptotic process Effects 0.000 abstract description 4
- 208000026435 phlegm Diseases 0.000 abstract description 4
- 230000019491 signal transduction Effects 0.000 abstract description 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000008076 immune mechanism Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 210000000822 natural killer cell Anatomy 0.000 abstract description 3
- 239000003223 protective agent Substances 0.000 abstract description 3
- 238000011127 radiochemotherapy Methods 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 230000004614 tumor growth Effects 0.000 abstract description 3
- 230000033115 angiogenesis Effects 0.000 abstract description 2
- 235000019441 ethanol Nutrition 0.000 description 20
- 230000000694 effects Effects 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 5
- 208000010916 pituitary tumor Diseases 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 244000223014 Syzygium aromaticum Species 0.000 description 3
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- FACFHHMQICTXFZ-UHFFFAOYSA-N 2-(2-phenylimidazo[1,2-a]pyridin-3-yl)ethanamine Chemical compound N1=C2C=CC=CN2C(CCN)=C1C1=CC=CC=C1 FACFHHMQICTXFZ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241001060310 Styracaceae Species 0.000 description 2
- 235000001361 Styrax officinalis Nutrition 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000019382 gum benzoic Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229940067137 musk ketone Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- CBMYJHIOYJEBSB-UHFFFAOYSA-N (10S)-3t.17t-Dihydroxy-10r.13c-dimethyl-(5cH.8cH.9tH.14tH)-hexadecahydro-1H-cyclopenta[a]phenanthren Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CCC21 CBMYJHIOYJEBSB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- RAJWOBJTTGJROA-UHFFFAOYSA-N (5alpha)-androstane-3,17-dione Natural products C1C(=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 RAJWOBJTTGJROA-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- PFCHFHIRKBAQGU-UHFFFAOYSA-N 3-hexanone Chemical compound CCCC(=O)CC PFCHFHIRKBAQGU-UHFFFAOYSA-N 0.000 description 1
- CVMWCRDXSQGRSJ-UHFFFAOYSA-N 3-methylcyclotridecan-1-one Chemical compound CC1CCCCCCCCCCC(=O)C1 CVMWCRDXSQGRSJ-UHFFFAOYSA-N 0.000 description 1
- RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 description 1
- RAJWOBJTTGJROA-WZNAKSSCSA-N 5alpha-androstane-3,17-dione Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 RAJWOBJTTGJROA-WZNAKSSCSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000003146 Lobelia chinensis Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001440 androstane derivatives Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- FUGDHQXYVPQGLJ-UHFFFAOYSA-N cyclotetradecanone Chemical compound O=C1CCCCCCCCCCCCC1 FUGDHQXYVPQGLJ-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种复方优基诺抗癌中药靶向制剂及其制作工艺,一种复方优基诺抗癌中药靶向制剂,其包括以下重量份配比的药物原料:优基诺原粉200份;麝香1份;其中,优基诺原粉包括以下药物原料:公丁香、天花粉、半枝莲、白花蛇舌草,本发明的有益效果是本方案公开的复方优基诺制剂是纯中药提取的多靶点广谱抗癌药物,并且可用作放化疗保护剂,其可抑制肿瘤细胞生长、抑制癌组织毛细血管生成,并激活肿瘤细胞凋亡因子,抑制肿瘤细胞信号传导,增强机体免疫机制,促进NK细胞和T细胞的生成,改善肿瘤患者体液内环境,促进细胞生理改善和平衡,祛痰湿、化瘀血、补元气,其制作工艺简单,制作周期短,生产成本低,便于推广使用。
Description
技术领域
本发明涉及药物制备技术领域,尤其是涉及一种复方优基诺抗癌中药靶向制剂及其制作工艺。
背景技术
在现有技术中,癌症是威胁人类生命的一大顽疾,它是在人体免疫力低下和各种内外因素,如化学、物理、生物、遗传等诱导下,细胞产生聚集性变异的结果。癌症其特点是癌细胞无休止地增生和通过淋巴、血行进行转移和扩散,消耗患者体内大量的营养物质,同时释放多种毒素,导致人体消瘦、无力、贫血、食欲不振、发热以及严重的脏器功能受损等。现阶段治疗癌症的医疗方法主要有西医和中医两种治疗方法,西医治疗目前主要是手术治疗、放疗、化疗及尚未成熟的靶向给药和细胞疗法等,其主要以治标为主,往往在去除或杀死癌细胞的同时,对人的机体正常组织产生很大的损伤或不可逆转的损害,对患者造成较大的痛苦,如头晕、呕吐、掉发、器官衰竭、免疫力降低等,而且费用较高,一般家庭难以承受。由于化疗的副作用比较大,使得不少肿瘤患者的化疗耐受力降低,导致化疗无法继续进行;且有些时候,癌细胞会转移至其他器官中,严重时甚至无法通过手术切除治疗,只能通过服用药物进行治疗。而近年来,抗癌中药可以弥补西医治疗的不足,使肿瘤患者可以在良好的耐受状态下接受抗癌中药治疗,取得一定的治疗效果。
申请号为:202110579476.5的中国发明专利公开了一种广谱抗瘤抗癌中药制剂,其由仙鹤草、蒲公英、白花蛇舌草、半枝莲、藤梨根、黄芪、灵芝、白术、黄土制成。然而该种广谱抗瘤抗癌中药制剂中的组成成分较多,制作工艺较为复杂,生产成本较高,不便于推广使用,其通过药性较强的药物直接对癌细胞造成破坏,对人体损伤较大,无法抑制癌组织毛细血管生成并且无法抑制肿瘤细胞信号传导,并且其无法在治疗过程中改善肿瘤患者体液内环境,容易导致细胞生理失衡。
发明内容
本发明的目的是提供一种复方优基诺抗癌中药靶向制剂及其制作工艺。
为实现上述目的,本发明提出的技术方案是:
一种复方优基诺抗癌中药靶向制剂,其包括以下重量份配比的药物原料:
优基诺原粉 200份;
麝香 1份;
其中,优基诺原粉包括以下药物原料:公丁香、天花粉、半枝莲、白花蛇舌草。
优基诺原粉包括以下重量份药物原料:
优基诺原粉包括以下重量份药物原料:
一种复方优基诺抗癌中药靶向制剂的制作工艺,制作工艺为采用上述重量份的药物原料进行如下步骤:
a、称药:按量称取公丁香、天花粉、半枝莲、白花蛇舌草并将其进行混合,重复混合后,粉碎为药粉;
b、提取:从乙醇贮藏中取出乙醇并与步骤a中制得的药粉进行充分混合,混合完成后,将药渣废弃,提取出混合药液;
c、过滤:对混合药液进行过滤,将滤液贮藏;
d、浓缩:对步骤c中制得的滤液进行真空浓缩,将经过真空浓缩后的药剂进行冷藏;
e、沉淀:向冷藏后的药剂中加入乙醇并进行沉淀反应,对药剂进行静置,药剂沉淀的同时乙醇浮在药剂上方以形成上清醇液,回收乙醇以得到流浸膏状态的药剂;
f、干燥:对流浸膏状态的药剂进行干燥处理以得到干浸膏状态的药剂,即优基诺原粉;
g、混合:向制得的优基诺原粉中加入麝香并混匀以得到复方优基诺制剂,优基诺原粉与麝香的质量比例为200:1。
步骤e中,对回收的乙醇进行精馏处理,精馏处理后将得到的乙醇贮藏以待使用。
将制得的复方优基诺制剂加入药学上可接受的载体以制成适于药用的制剂。
本发明的有益效果是:
本方案公开的复方优基诺制剂是纯中药提取的多靶点广谱抗癌药物,并且可用作放化疗保护剂,其可抑制肿瘤细胞生长、抑制癌组织毛细血管生成,并激活肿瘤细胞凋亡因子,抑制肿瘤细胞信号传导,增强机体免疫机制,促进NK细胞和T细胞的生成,改善肿瘤患者体液内环境,促进细胞生理改善和平衡,祛痰湿、化瘀血、补元气,其制作工艺简单,制作周期短,生产成本低,便于推广使用。
附图说明
图1是制作工艺流程图。
具体实施方式
下面结合附图对本发明作进一步详细描述,
一种复方优基诺抗癌中药靶向制剂,其包括以下重量份配比的药物原料:
优基诺原粉 200份;
麝香 1份;
其中,优基诺原粉包括以下药物原料:公丁香、天花粉、半枝莲、白花蛇舌草。
优基诺原粉包括以下重量份药物原料:
优基诺原粉包括以下重量份药物原料:
其中,1kg优基诺原粉中加入5g麝香。
一种复方优基诺抗癌中药靶向制剂的制作工艺,制作工艺为采用上述重量份的药物原料进行如下步骤:
a、称药:按量称取公丁香、天花粉、半枝莲、白花蛇舌草并将其进行混合,重复混合后,粉碎为药粉;
b、提取:从乙醇贮藏中取出乙醇并与步骤a中制得的药粉进行充分混合,混合完成后,将药渣废弃,提取出混合药液;
c、过滤:对混合药液进行过滤,将滤液贮藏;
d、浓缩:对步骤c中制得的滤液进行真空浓缩,将经过真空浓缩后的药剂进行冷藏;
e、沉淀:向冷藏后的药剂中加入乙醇并进行沉淀反应,对药剂进行静置,药剂沉淀的同时乙醇浮在药剂上方以形成上清醇液,回收乙醇以得到流浸膏状态的药剂;
f、干燥:对流浸膏状态的药剂进行干燥处理以得到干浸膏状态的药剂,即优基诺原粉;
g、混合:向制得的优基诺原粉中加入麝香并混匀以得到复方优基诺制剂,优基诺原粉与麝香的质量比例为200:1。
步骤e中,对回收的乙醇进行精馏处理,精馏处理后将得到的乙醇贮藏以待使用。
将制得的复方优基诺制剂加入药学上可接受的载体以制成适于药用的制剂,本发明制作工艺流程图如图1所示。
其中,本方案中复方优基诺制剂可以是任何可药用的剂型,这些剂型包括:片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含片、颗粒剂、丸剂、散剂、滴丸剂等。优选的口服剂型如:片剂、胶囊剂、颗粒剂、丸剂、散剂、滴丸剂。
其中,复方优基诺制剂制成胶囊时,其灌装规格为0.45g/胶囊,其服用方法为一天两次,一次一粒,每天早晚饭后半小时服用,暂未发现其毒副作用。
临床典型案例:
案例1:杨某,女,系河北蠡县人,2016年在北京确诊为宫颈癌晚期,已不能手术,几次化疗之后,服用“复方优基诺多靶点抗癌制剂”,现肿块完全消失,各项指标完全正常,已正常生活超过六年。
案例2:项某,男,系北京人,90岁,2016年发现直肠癌晚期,由于年岁已高,难以承受手术,故采用“复方优基诺多靶点抗癌制剂”,确保了晚年的正常生活。
案例3:沈某,女,系内蒙人,36岁,2016年9月发现胰腺癌晚期,骨转移,被医院诊断为不治,被判定只有三个月到六个月的生存期,采用“复方优基诺多靶点抗癌制剂”后至今生活质量和正常人一样。
案例4:王某,女,系廊坊人,2019年发现脑垂体瘤,其就诊医院的结论为:脑垂体瘤很难缩小,如不增长或缓慢增长就属幸运,其自2019年8月开始使用“复方优基诺多靶点抗癌制剂”后,至2020年4月复查,脑垂体瘤直径缩小三分之一,2020年8月份检测,各项指标均正常。
案例5:刘某,男,71岁,肝癌晚期,剧烈疼痛,必须注射“杜冷丁”、“吗啡”才能忍受,使用“复方优基诺多靶点抗癌制剂”后,四天停用“杜冷丁”,变为轻度疼痛,两周后疼痛消失。
案例6:杨某,男,系天津人,2022年7月22日检测发现食道癌,癌胚抗原CEA高达684,自7月25日起,采用“复方优基诺多靶点抗癌制剂”进行治疗,至8月11日,CEA由684降至322.
案例7:徐某,女,系武汉人,39岁,母女三人均患乳腺癌,因担心术后复发,手术后进行大剂量化疗,并配合“复方优基诺多靶点抗癌制剂”进行治疗,在同舍病友,同药物、同剂量都不能承受的情况下,其仍可正常进行社会活动,且白细胞长期处于正常水平,目前生活正常。
案例8:王某,女,2022年7月职工体检发现肺部存在5mm的结节,肿瘤标志物糖类抗原指标超标,之后服用“复方优基诺多靶点抗癌制剂”,5个月后去医院进行检查,各项指标均已正常,肺部结节消失,并且其哥哥患有肺部肿瘤,在服用“复方优基诺多靶点抗癌制剂”后,肺部肿瘤在逐渐减小。
案例9:李某,女,52岁,2016年10月在北京确诊胰腺癌,做了胰腺尾部切除手术后,一直服用“复方优基诺多靶点抗癌制剂”,未发现不良反应,两个月后恢复正常生活。
案例10:李某,男,59岁,系天津人,2022年8月份因咳嗽严重在医院检查出肺癌,使用“复方优基诺多靶点抗癌制剂”和中药组方用药1周后咳嗽减轻,两周后食欲与体力恢复,咳嗽症状消失,用药一月后去医院复查,肿块无增大现象,至今仍在服用“复方优基诺多靶点抗癌制剂”。
案例11:何某,男,系池州人,2016年9月在医院检查出纤维肉瘤,在上海某医院进行手术,术后仍持续生长,后服用“复方优基诺多靶点抗癌制剂”,并配合外用“优基诺乳液”,半年后,基本结痂,恢复正常。
其中,本发明的中药组合物原料特点、辨证用药、组方原理及功效:
公丁香:公丁香为常用中药,其性辛,味温。入肺、脾、胃、肾四经;功效:温中、暖肾、降逆。主治:治呃逆、呕吐、反胃、痢疾、心腹冷痛、痃癖、疝气、癣症,是我国传统进口"南药"之一,始载于《药性论》;现代研究表明,丁香含挥发油,油中主要含丁香油酸、乙酰丁香油酸及丁香烯、甲基正戊酮、甲基正庚酮、香荚兰醛等成分;具抑菌及驱虫作用,用作芳香,镇痉驱风剂,治疗胃病,腹痛、呕吐、神经痛、牙痛等疾病
天花粉:甘、微苦,微寒为清热泻火类药物,其具体功效是清热泻火,生津止渴,排脓消肿;主治:治热病口渴、消渴、黄疸、肺燥咳血、痈肿、痔痿。
半支莲:全草入药,性寒,味酸;具有清热解毒、活血祛瘀、消肿止痛、抗癌等功能。全草含多种维生素、微量元素及氨基酸等成分;治食道癌、胃癌、子宫癌等各种癌肿,用于肝炎,痈疮肿毒及阑尾炎。
白花蛇舌草:味甘、淡,性凉。清热解毒,利湿消痈,抗癌;用于恶性肿瘤,肠痈,咽喉肿痛,湿热黄疸,小便不利,疮疖肿毒,毒蛇咬伤。
麝香:麝香是脊索动物门哺乳纲麝科动物的成熟雄体香囊中的干燥分泌物,其具有开窍醒神、活血通经、消肿止痛的功效,其性温、无毒、味苦;入心、脾、肝经,有开窍、辟秽、通络、散淤之功能。主治中风、痰厥、惊痫、中恶烦闷、心腹暴痛、跌打损伤、痈疽肿毒;许多临床材料表明,冠心病患者心绞痛发作时,或处于昏厥休克时,服用以麝香为主要成分的苏合丸,病情可以得到缓解,其含麝香酮、降麝香酮、麝香醇、麝香吡喃、麝香吡啶、羟基麝香吡啶-A、羟基麝香吡啶-B、3-甲基环十三酮、环十四烷酮等;亦含胆甾-4-烯-3-酮、胆甾醇和它的酯类、睾丸酮、雌乙醇、5α-雄烷-3,17-二酮等11种雄烷衍生物。尚含蛋白质与氨基酸,麝香中含蛋白质约25%.麝香中发现一种分子量为1000左右的肽类活性物质,并分离出一种分子量约5000~6000的多肽,其醇溶物中含4种游离氨基酸,即精氨酸,脯氨酸、甘氨酸和丙氨酸.将醇溶物用丙酮、甲醇和水提取,水解后的氨基酸分析表明:甲醇提取物中氨基酸含量最高,其中以天门冬氨酸、丝氨酸、胱氨酸等含量最高;丙酮提取物中谷氨酸、缬氨酸、组氨酸和甘氨酸较高。
工作原理:
本方案中的纯中药成分“复方优基诺(Co-Eugenol)”多靶点抗癌组方,将中医与现代分子生物的先进技术相结合,实现药物的多靶点作用,兼具中药活血化瘀,增强免疫机制,中医药创新抗癌新组方,其主要原理是依靠中药中高纯度的五环三萜、二萜、肿瘤凋亡因子(Caspase)、倍半萜类物质,依据靶向治疗理论并结合中医传统经典理论,按比例配伍,同时配合各类已被证实有显著效果的传统中药材,如麝香进行复配而成,克服了化学合成靶向药物“分子单纯,易产生抗药性”和“副反应强”的缺点,也克服了普通中成药成分过于复杂,抗癌成分“庞杂”、模糊不清、广泛有效却效不突出的缺点。兼具化学合成靶向抗癌药物抗癌成份清晰、目标集中、效果显著和中药效果温和、副作用小,作用范围广泛,不易产生抗药性和耐药性的特点。
本发明的有益效果是本方案公开的复方优基诺制剂是纯中药提取的多靶点广谱抗癌药物,并且可用作放化疗保护剂,其可抑制肿瘤细胞生长、抑制癌组织毛细血管生成,并激活肿瘤细胞凋亡因子,抑制肿瘤细胞信号传导,增强机体免疫机制,促进NK细胞和T细胞的生成,改善肿瘤患者体液内环境,促进细胞生理改善和平衡,祛痰湿、化瘀血、补元气,其制作工艺简单,制作周期短,生产成本低,便于推广使用。
以上对本发明的一个实施例进行了详细说明,但所述内容仅为本发明的较佳实施例,不能被认为用于限定本发明的实施范围。凡依本发明申请范围所作的均等变化与改进等,均应仍归属于本发明的专利涵盖范围之内。
Claims (6)
1.一种复方优基诺抗癌中药靶向制剂,其特征在于,其包括以下重量份配比的药物原料:
优基诺原粉 200份;
麝香 1份;
其中,优基诺原粉包括以下药物原料:公丁香、天花粉、半枝莲、白花蛇舌草。
2.如权利要求1所述的一种复方优基诺抗癌中药靶向制剂,其特征在于,优基诺原粉包括以下重量份药物原料:
3.如权利要求2所述的一种复方优基诺抗癌中药靶向制剂,其特征在于,优基诺原粉包括以下重量份药物原料:
4.一种复方优基诺抗癌中药靶向制剂的制作工艺,其特征在于,制作工艺为采用如权利要求3中所述重量份的药物原料进行如下步骤:
a、称药:按量称取公丁香、天花粉、半枝莲、白花蛇舌草并将其进行混合,充分混合后,粉碎为药粉;
b、提取:从乙醇贮藏中取出乙醇并与步骤a中制得的药粉进行充分混合,混合完成后,将药渣废弃,提取出混合药液;
c、过滤:对混合药液进行过滤,将滤液贮藏;
d、浓缩:对步骤c中制得的滤液进行真空浓缩,将经过真空浓缩后的药剂进行冷藏;
e、沉淀:向冷藏后的药剂中加入乙醇并进行沉淀反应,对药剂进行静置,药剂沉淀的同时乙醇浮在药剂上方以形成上清醇液,回收乙醇以得到流浸膏状态的药剂;
f、干燥:对流浸膏状态的药剂进行干燥处理以得到干浸膏状态的药剂,即优基诺原粉;
g、混合:向制得的优基诺原粉中加入麝香并混匀以得到复方优基诺制剂,优基诺原粉与麝香的质量比例为200:1。
5.如权利要求4所述的一种复方优基诺抗癌中药靶向制剂的制作工艺,其特征在于,步骤e中,对回收的乙醇进行精馏处理,精馏处理后将得到的乙醇贮藏以待使用。
6.如权利要求5所述的一种复方优基诺抗癌中药靶向制剂的制作工艺,其特征在于,将制得的复方优基诺制剂加入药学上可接受的载体以制成适于药用的制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211530592.9A CN116870065A (zh) | 2022-12-01 | 2022-12-01 | 一种复方优基诺抗癌中药靶向制剂及其制作工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211530592.9A CN116870065A (zh) | 2022-12-01 | 2022-12-01 | 一种复方优基诺抗癌中药靶向制剂及其制作工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116870065A true CN116870065A (zh) | 2023-10-13 |
Family
ID=88261042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211530592.9A Pending CN116870065A (zh) | 2022-12-01 | 2022-12-01 | 一种复方优基诺抗癌中药靶向制剂及其制作工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116870065A (zh) |
-
2022
- 2022-12-01 CN CN202211530592.9A patent/CN116870065A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102697035A (zh) | 虫草褔寿丹 | |
CN102697893B (zh) | 黑树莓提取物在制备治疗胃癌药物中的应用 | |
CN102861284B (zh) | 一种治疗非小细胞肺癌的中药复方制剂及其制备方法 | |
CN101352557B (zh) | 治疗胃癌的中药制剂及其制备方法 | |
CN101850032B (zh) | 一种具有抗肿瘤作用的中药组合物及其制备方法和应用 | |
CN103920034B (zh) | 减轻肿瘤病人化疗副反应的中药组合物及制法 | |
CN115120689A (zh) | 欣力康复方制剂在制备药物中的应用 | |
CN105456311A (zh) | 一种用于防治乳腺癌、肝癌的沙棘提取物及其制备方法和其应用 | |
CN108186794B (zh) | 一种治疗肺癌的中药组合物及其制备方法和应用 | |
WO2018171672A1 (zh) | 一种抗癌药物组合物及其用途 | |
CN107266599B (zh) | 金针菇多糖、提取方法及其在制备治疗功能性便秘药物方面的应用 | |
CN118434431A (zh) | 一种中药组合物及其制备方法与应用 | |
CN108452240B (zh) | 一种抗肿瘤的中药组合物及其应用 | |
CN103191167B (zh) | 华泽兰的应用 | |
KR20200081553A (ko) | 진해거담 예방 및 개선용 조성물 | |
CN116870065A (zh) | 一种复方优基诺抗癌中药靶向制剂及其制作工艺 | |
CN100406026C (zh) | 一种治疗慢性胃炎、胃癌的药物及其制备方法 | |
CN108283668A (zh) | 一种含美洲大蠊提取物的胃溃疡组合物及其制备方法 | |
CN103536862B (zh) | 防治胃癌的益气活血复方中药制剂及其制备方法 | |
CN103463253B (zh) | 一种癌症术后防复发的真菌药物及其生产方法 | |
KR100316379B1 (ko) | 암치료용 한방 조성물 | |
CN105213780B (zh) | 一种治疗慢性胃炎的中药组合物及其应用 | |
CN108578501A (zh) | 具有抗癌功效的人参组合物 | |
CN111298061B (zh) | 一种清热解毒、祛瘀散结的中药组合物及其制备方法 | |
CN117462620B (zh) | 一种治疗肺癌的中药组方及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |